Phase II trial

TORONTO, Canada, August 31, 2026 Arch Biopartners Inc. announced that it has received central Institutional Review Board (IRB) approval...

NANJING, China, August 6, 2026 Leads Biolabs announced that its Phase II clinical study evaluating Opamtistomig (LBL-024) in combination...

CAMBRIDGE, Mass., August 5, 2026 Obsidian Therapeutics announced the enrollment of the first patient in the registration-enabling cohort of...

MIAMI, August 5, 2026 Summit Therapeutics announced the launch of the Phase II/III HARMONi-GU1 study, the company’s first global...

NANJING, China, July 30, 2026 Leads Biolabs announced that its Phase II clinical trial evaluating Opamtistomig (LBL-024), a proprietary...

PORTLAND, Ore., July 29, 2026 Trace Biosciences, Inc. has secured a strategic investment from Axogen, Inc. to accelerate clinical...

SYDNEY, Australia – July 24, 2026 Immutep Limited has announced that an abstract from its investigator-initiated Phase II EFTISARC-NEO...

QUÉBEC, Canada, July 21, 2026 Devonian Health Group has received Health Canada authorization to initiate a Phase II/III clinical...

HONG KONG, July 20, 2026 Akeso, Inc. has announced a significant milestone in its oncology pipeline with the first...

BARCELONA, Spain, July 17, 2026 Almirall S.A. has announced that the European Medicines Agency (EMA) has accepted the Marketing...